IPO Roundup: Danaher's dental spin-off Envista shows its pearly whites in strong public debut

The Brea, California company offered 26.8 million shares at $28 per share, within its expected range of $21 to $24

Person in suit touching IPO graphic
IGM Biosciences also got off to a positive start, Datadog increased expectations, but We Company opted to postpone

Envista Holdings Corp (NYSE:NVST), a dental supply company being spun off from Danaher Corporation (NYSE:DHR), raised $589 million in its IPO. The Brea, California company offered 26.8 million shares at $28 per share, within its expected range of $21 to $24. 

The stock opened trading at $25.94 and rose higher to $26.30, nearly 20% above its IPO price.

IGM Biosciences Inc (NASDAQ:IGMS), an immuno-oncology company based in Mountain View, California, had an upsized $175 million IPO. The company offered 10.9 million shares, 3.1 million more than expected, at a price of $16 per share, the center of its $15-to-$17 range. 

Trading opened at $18.31 and ticked slightly higher to $18.42, 15% above its IPO price.

READ: IPO Roundup: Cloud-monitoring company Datadog chases $7 billion valuation this week

Additionally, business monitoring and analytics company Datadog Inc, bumped up its proposed IPO range ahead of its Wednesday night pricing. 

The company said it now plans to offer 24 million shares at a price between $24 and $26 per share, up from its prior estimate between $19 and $22, according to a report from broker Renaissance Capital. That could net the company $600 million, compared to its original expectations of $492 million.

Elsewhere, the owner of WeWork opted to postpone its IPO on Tuesday, less than a week before the company was expected to go public. It’s been a rocky ride for the The We Company, which cut its market valuation to between $10 billion and $12 billion from the $47 billion it calculated in January.

Contact Andrew Kessel at [email protected] 

Follow him on Twitter @andrew_kessel

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Algernon Pharmaceuticals receives US FDA clearance for Phase 2b/3 human study

Algernon Pharmaceuticals Inc. (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with major news for the company that they have received clearance from the U.S. FDA for its multinational Phase 2b/3 study of Ifenprodil as a potential treatment for...

4 hours, 2 minutes ago

2 min read